Perrigo Benefits From McNeil Recall, Prepares Infant Formula Launches
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson's extensive recall of leading brand name analgesics spurred sales growth for Perrigo's private-label products in the category during the firm's most recent earnings period
You may also be interested in...
Perrigo's Generic Mucinex Becomes A Long Shot To Launch In Fiscal 2011
Perrigo further delays plans for a generic version of Reckitt Benckiser's Mucinex, saying the product it once touted as a 2010 highlight may not emerge even during the firm's fiscal 2011
Reckitt Would Add Durex, Scholl Brands With SSL Acquisition
Reckitt Benckiser moves again to grow its consumer products business, particularly in Asian markets, with an offer to acquire Durex condoms and Scholl foot care products manufacturer SSL International
Perrigo Gains Pole Position In Private-Label Allegra Race
Perrigo cuts to the front of the queue for launching private-label versions of OTC Allegra, acquiring from Teva the exclusive U.S. sales and distribution rights to generic equivalents of the allergy drug